Longevity & AgingNew Drug UDP-003 Safely Clears Toxic Cholesterol Behind Artery Plaques in Phase 1 Trial
Cyclarity's experimental drug UDP-003 has completed a successful Phase 1 trial in 72 healthy volunteers in Australia. The drug targets 7-ketocholesterol (7KC), a toxic oxidized cholesterol that accumulates inside artery plaques and drives atherosclerosis. Unlike standard cardiovascular drugs that lower LDL or reduce inflammation, UDP-003 is designed to grab 7KC directly and remove it from the body through urine. The trial showed no serious adverse events, no dropouts, and clean pharmacokinetics — the drug passes through the body unchanged within three hours. Crucially, participants excreted measurable 7KC in urine for the first time, with a clear dose-response relationship. Researchers now plan to advance to Phase 2 testing in actual atherosclerosis patients at the highest tested dose.
